MyOme Partners with Natera to Expand Rare Disease Diagnostics with Methylation Analysis
Event summary
- MyOme is integrating methylation analysis (epigenetic signatures) into its whole-genome platform to improve rare disease diagnostics.
- MyOme has partnered with Natera to launch Zenith™, a premium exome and genome testing solution, expanding patient access through Natera’s network.
- Zenith will be commercially available through Natera starting immediately, leveraging Natera’s EMR integration and clinical support.
- Methylation analysis will be automatically integrated into eligible rare disease exome and genome analysis orders starting in early Q2 2026.
- MyOme is sponsoring Medical Genetics Awareness Week (March 10–14).
The big picture
The integration of methylation analysis into genomic sequencing represents a significant shift towards more comprehensive rare disease diagnostics, addressing a critical pain point in the healthcare system – the lengthy and costly diagnostic odyssey. This partnership between MyOme and Natera, leveraging Natera’s established distribution network, positions MyOme to capture a larger share of the growing rare disease diagnostics market, which is increasingly driven by the demand for more precise and timely diagnoses.
What we're watching
- Adoption Rate
- The speed at which Zenith™ is adopted by healthcare providers will determine the immediate financial impact of the Natera partnership, and reveal the true market demand for methylation analysis in rare disease diagnostics.
- Clinical Utility
- The extent to which the integrated methylation analysis demonstrably improves diagnostic accuracy and reduces diagnostic delays will be critical for securing reimbursement and expanding clinical utility.
- Platform Expansion
- MyOme’s ability to rapidly expand the list of disease areas covered by its methylation analysis platform will dictate its long-term competitive advantage in the rare disease diagnostics market.
Related topics